The purpose of this study is to learn about using the imaging to make images of the lungs and nose with the long-term goal of the research leading to potential treatments and new therapies for patients with cystic fibrosis.

Lung Disease is the predominate cause of morbidity and mortality in patients with cystic fibrosis (CF). A better understanding of the primary pathogenesis of CF is essential in order to reveal the features that may lead to the onset of progressive lung disease. Discerning the nature of the CF defect could resolve longstanding controversy and result in a new therapeutic opportunity that may address pathophysiology. Recently the investigators have developed an innovative technology, termed 1-µm resolution optical coherence tomography (µOCT), which enables real-time cross-sectional microscopy of the functional epithelial surface of living airways.

THE INCLUSION CRITERIA:

• Patients diagnosed with CF or healthy normal controls with no respiratory disease
• Patients must be over the age of 14
• Patient must be able to give informed consent

THE EXCLUSION CRITERIA:

• Patients with recent respiratory infection requiring antibiotics or corticosteroids in the last 4 weeks (excluding routine perioperative antibiotics)
• Patients with major sinus surgery that will alter the nasal anatomy and preclude imaging of the nares
• Any condition that in the opinion of the investigator will alter the safety of pilot testing in the operating room
• Female subjects who are pregnant

Patients with CF, COPD, Sinusitis, PCD and COVID 19 will be enrolled.